Overview
I am a Research Associate Trial Manager at Centre for Trials Research. My main expertise lies in trial management with focus on setting up and managing phase II and phase III multicentre clinical trials. I currently manage four trials, two high risk CTIMP trials and two radiotherapy interventional trials:
COPELIA a phase II three-arm Randomised Controlled Trial which is evaluating whether cediranib and olaparib can improve time to cancer progression in endometrial cancer.
CEBOC is a single-arm phase II trial is investigating the safety of treating ovarian cancer patients who at high risk of bowel obstruction with cediranib.
PEARL is an interventional phase II feasibility study looking to optimize the use of PET imaging for HPV positive head and neck cancer patients undergoing chemo-radiotherapy. It aims to reduced side effects from the treatment and an improved quality of life in the long term.
SCC-AFTER a two-arm phase III radiotherapy intervention randomised control trial in cutaneous squamous cell carcinoma (cSCC) a common skin cancer. The SCC-After trial aims to definitively show whether giving adjuvant radiotherapy plus active monitoring (versus active monitoring alone) is beneficial in reducing loco-regional recurrence of high-risk primary cSCC following surgery. The outcomes from this study aim to provide robust and reliable evidence to guide future national treatment recommendations and improve patient outcomes.
Publication
2024
- Murphy, A. D. et al. 2024. Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial. International Journal of Gynecological Cancer 34, pp. 1034-1040. (10.1136/ijgc-2024-005455)
2022
- Fennell, D. A. et al. 2022. Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine 52, article number: 101595. (10.1016/j.eclinm.2022.101595)
Articles
- Murphy, A. D. et al. 2024. Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial. International Journal of Gynecological Cancer 34, pp. 1034-1040. (10.1136/ijgc-2024-005455)
- Fennell, D. A. et al. 2022. Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine 52, article number: 101595. (10.1016/j.eclinm.2022.101595)
Biography
Research Associate/Trial Manager - Centre for Trials Research 17/10/2016 - Present
I am experienced in trial management for a range of trials and studies including large multi-centre Clinical Trials of Investigational Medical Products (CTIMP) and interventional randomised controlled trials (RCT). I take responsibility of the set-up and day to day management of industry and academia sponsored trials and studies. I currently work on four trials: CEBOC, COPELIA, PEARL, and SCC-AFTER.
Regulatory Affairs Manager - Centre for Trials Research 23/05/2018 - 31/05/2019
Responsible for the development and co-ordination of high-quality Regulatory Affairs (RA) work and Pharmacovigilance & Safety (PV & S) systems within CTR. I provided advice, guidance, and training on national, EU and international processes to internal and external stakeholders. EudraVigilance certificate holder. Line managed the centralised PV & S team developing staff to deliver trial and team outputs.
Research Assistant/Data Manager - Centre for Trials Research 17/06/2013 - 17/10/2016
Responsible for data management from database development to quantitative data collection, data cleaning for analysis for the following studies: PIN, VIM, SKOPOS, CONSCOP, SUCCINCT, FRAGMATIC, I-START and FLIGHT.
Professional memberships
I am member of the UK Trial Manager Network (UKTMN), CTR Public Involvement & Engagement Hub, CTR Data Life Cycle Group, CTR Learning & Development Group and CTR Risk Assessment Group.
Contact Details
+44 29206 87465
Neuadd Meirionnydd, Floor 6, University Hospital of Wales, Heath Park, Cardiff, CF14 4YS